OFFICIAL LEGAL TITLE
Safeguarding Patients and Taxpayers Act
FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 118_S_1589.
Which chamber initiated this legislation?
This legislation was initiated in the Senate.
When did the legislative process begin?
The process officially started on 2023-05-11.
What are the main provisions?
Key points include:
- The government must regularly report to Congress on all expenditures related to the drug price negotiation program, including contracts with external entities and staffing costs.
- New requirements are established to prevent fraud and abuse, ensuring that only eligible individuals and entities benefit from the lower, negotiated drug prices.
- Funds designated for drug price negotiations cannot be easily transferred or used to create new, unauthorized government programs.
What is the specific legal status?
The current status is Expired.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Sen. Tillis, Thomas [R-NC].
What is the latest detailed status?
The latest detailed status is: Introduced in Senate
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.
What is the impact of this bill?
We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.